J 2024

Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drug

HOFERKOVÁ, Eva; Václav ŠEDA; Soňa CESNÁRIKOVÁ; Jan VERNER; Tomáš LOJA et. al.

Basic information

Original name

Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drug

Authors

HOFERKOVÁ, Eva; Václav ŠEDA; Soňa CESNÁRIKOVÁ; Jan VERNER; Tomáš LOJA; Květoslava MATULOVÁ; Hana SKUHROVÁ FRANCOVÁ; Eva ONDROUŠKOVÁ; Daniel FILIP; Nicolas BLAVET; Miroslav BOUDNÝ; Gabriela MLADONICKÁ PAVLASOVÁ; Josef VEČEŘA; Laura ONDRIŠOVÁ; Petra PAVELKOVÁ; Kryštof HLAVÁČ; Lenka KOŠŤÁLOVÁ; Androniki MICHAELOU; Šárka POSPÍŠILOVÁ; Jana DORAZILOVÁ; Václav CHOCHOLA; Josef JAROŠ; Michael DOUBEK; Marie JAROŠOVÁ; Aleš HAMPL; Lucy VOJTOVÁ; Leoš KŘEN; Jiří MAYER and Marek MRÁZ

Edition

Leukemia, London, Nature Publishing Group, 2024, 0887-6924

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Organization

Středoevropský technologický institut – Repository – Repository

DOI

http://dx.doi.org/10.1038/s41375-024-02284-w

UT WoS

001247878900001

EID Scopus

2-s2.0-85195873378

Keywords in English

stromal cells; T cell factors; CLL cell proliferation

Links

LX22NPO5102, research and development project. MUNI/A/1558/2023, interní kód Repo. MUNI/A/1598/2023, interní kód Repo. NU23-08-00448, research and development project. 802644, interní kód Repo. NCMG III, large research infrastructures.
Changed: 19/3/2025 00:51, RNDr. Daniel Jakubík

Abstract

V originále

Several in vitro models have been developed to mimic chronic lymphocytic leukemia (CLL) proliferation in immune niches; however, they typically do not induce robust proliferation. We prepared a novel model based on mimicking T-cell signals in vitro and in patient-derived xenografts (PDXs). Six supportive cell lines were prepared by engineering HS5 stromal cells with stable expression of human CD40L, IL4, IL21, and their combinations. Co-culture with HS5 expressing CD40L and IL4 in combination led to mild CLL cell proliferation (median 7% at day 7), while the HS5 expressing CD40L, IL4, and IL21 led to unprecedented proliferation rate (median 44%). The co-cultures mimicked the gene expression fingerprint of lymph node CLL cells (MYC, NFκB, and E2F signatures) and revealed novel vulnerabilities in CLL-T-cell-induced proliferation. Drug testing in co-cultures revealed for the first time that pan-RAF inhibitors fully block CLL proliferation. The co-culture model can be downscaled to five microliter volume for large drug screening purposes or upscaled to CLL PDXs by HS5-CD40L-IL4 ± IL21 co-transplantation. Co-transplanting NSG mice with purified CLL cells and HS5-CD40L-IL4 or HS5-CD40L-IL4-IL21 cells on collagen-based scaffold led to 47% or 82% engraftment efficacy, respectively, with ~20% of PDXs being clonally related to CLL, potentially overcoming the need to co-transplant autologous T-cells in PDXs.
Displayed: 16/7/2025 20:56